OmniAb, Inc. (OABI) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $4.06: Euphoria warning: extreme positivity (+0.93) + overbought RSI 95; Near 52-week high (-11.4% away).
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform... Read more
Sell if holding. Multiple concerning factors at $4.06: Euphoria warning: extreme positivity (+0.93) + overbought RSI 95; Near 52-week high (-11.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-08-17Recent Developments — OmniAb, Inc.
Latest news
- NEWS H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Mo — benzinga Aug 17, 2026 positive
- NEWS Why Is Omniab Stock Rallying After Eli Lilly Deal? — benzinga Aug 17, 2026 positive
- NEWS 12 Health Care Stocks Moving In Monday's Pre-Market Session — benzinga Aug 17, 2026 neutral
- NEWS Market-Moving News for August 17th — benzinga Aug 17, 2026 neutral
- NEWS Omniab Revises 2026 Cash and Cash Equivalents Financial Guidance to Between $49M and $53M Vs. $37-$41M Previously — benzinga Aug 17, 2026 positive
Generated 2026-08-17T15:12:20Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $4.06: Euphoria warning: extreme positivity (+0.93) + overbought RSI 95; Near 52-week high (-11.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $3.77. Score 5.8/10, moderate confidence.
Take-profit target: $6.38 (+57.5% upside). Prior stop was $3.77. Stop-loss: $3.77.
Near 52-week high (-11.4% away); Euphoria warning: extreme positivity (+0.93) + overbought RSI 95; Overbought (RSI 95).
OmniAb, Inc. trades at a P/E of N/A (forward -11.4). TrendMatrix value score: 6.0/10. Verdict: Sell.
13 analysts cover OABI with a consensus score of 4.2/5. Average price target: $7.
What does OmniAb, Inc. do?OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies,...
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.